Pharmaceutical firms not included in President Trump's drug pricing agreements are now trying to negotiate their own deals. This move is aimed at avoiding potential tariffs and new pricing regulations. Industry insiders reveal that these companies are reaching out to the White House and Medicare off
Danish and Greenlandic veterans are feeling let down by the US. They fought alongside American troops in various missions. Now, they are upset by the US's recent actions. The US wanted to take Greenland. This caused a lot of tension. The US president even threatened to use military force. But later
Pharmaceutical giants are making headlines again, but this time, it's not about new drugs. Merck and eight other big players have joined Pfizer, Lilly, and Novo in signing Most Favored Nation (MFN) deals. These agreements aim to make medicines more affordable by tying drug prices to the lowest price
Pharmaceutical stocks have been overlooked for years. But now, AI is changing the game. It can speed up drug development. This could cut the time from 15 years to just 6. That's big news for the industry. Two companies stand out. Becton Dickinson (BDX) and the BlackRock Health Sciences Fund (BME).
